Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Rheumatoid Arthritis

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 14 articles:
HTML format



Single Articles


    February 2024
  1. VAN DER HELM-VAN MIL AHM
    Abatacept in individuals with autoantibody-positive arthralgia at risk for rheumatoid arthritis.
    Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055.
    PubMed    


  2. RECH J, Tascilar K, Hagen M, Kleyer A, et al
    Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.
    Lancet. 2024 Feb 13:S0140-6736(23)02650-8. doi: 10.1016/S0140-6736(23)02650.
    PubMed     Abstract available


  3. COPE AP, Jasenecova M, Vasconcelos JC, Filer A, et al
    Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
    Lancet. 2024 Feb 13:S0140-6736(23)02649-1. doi: 10.1016/S0140-6736(23)02649.
    PubMed     Abstract available


    November 2023
  4. DI MATTEO A, Bathon JM, Emery P
    Rheumatoid arthritis.
    Lancet. 2023;402:2019-2033.
    PubMed     Abstract available


    June 2023
  5. SAAVEDRA FT, Sierra LL, Zuluaica AM, Botero EC, et al
    Diagnosing Caplan syndrome in a patient with silicosis and rheumatoid arthritis: imaging shows miliary pattern and cavity lung lesions.
    Lancet. 2023;401:2148.
    PubMed    


    May 2023
  6. CONRAD N, Misra S, Verbakel JY, Verbeke G, et al
    Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
    Lancet. 2023 May 5:S0140-6736(23)00457-9. doi: 10.1016/S0140-6736(23)00457.
    PubMed     Abstract available


    February 2023
  7. MORAND EF, Vital EM, Petri M, van Vollenhoven R, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
    Lancet. 2023 Feb 24:S0140-6736(22)02607-1. doi: 10.1016/S0140-6736(22)02607.
    PubMed     Abstract available


    September 2022
  8. BOWMAN SJ, Dorner T, Mariette X, Luo WL, et al
    Ianalumab in Sjogren's syndrome: what can we learn from lupus trials? - Authors' reply.
    Lancet. 2022;400:808-809.
    PubMed    


  9. DYBALL S, Parker B, Bruce IN
    Ianalumab in Sjogren's syndrome: what can we learn from lupus trials?
    Lancet. 2022;400:807-808.
    PubMed    


    July 2022
  10. KRIJBOLDER DI, Verstappen M, van Dijk BT, Dakkak YJ, et al
    Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial
    Lancet. 2022;400:283-294.
    PubMed     Abstract available


  11. RECH J, Schett G
    Towards preventive treatment of rheumatoid arthritis.
    Lancet. 2022;400:253-255.
    PubMed    


    January 2022
  12. SARAUX A, Devauchelle-Pensec V
    Primary Sjogren's syndrome: new beginning for evidence-based trials.
    Lancet. 2022;399:121-122.
    PubMed    


  13. BOWMAN SJ, Fox R, Dorner T, Mariette X, et al
    Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Lancet. 2022;399:161-171.
    PubMed     Abstract available


    August 2021
  14. MCLORNAN DP, Pope JE, Gotlib J, Harrison CN, et al
    Current and future status of JAK inhibitors.
    Lancet. 2021;398:803-816.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.